Ablu 50 Mg Tablet (Abiraterone)
Price range: $41.58 through $60.38Required
| Pack Size | Price | Unit Price | Quantity | |
|---|---|---|---|---|
| 30 Tablet/s | $41.58 | $1.39 / tablet | ||
| 60 Tablet/s | $51.73 | $0.86 / tablet | ||
| 90 Tablet/s | $60.38 | $0.67 / tablet |
About Ablu 50 Mg Tablet (Abiraterone)
Medicine information
- Indication
- Bicalutamide 50 mg is used with a luteinizing hormone-releasing hormone (LHRH) analog for metastatic prostate cancer.
- Strength
- 50 mg
Medicine overview
Ablu 50 mg Tablet contains bicalutamide, not abiraterone. Bicalutamide is a nonsteroidal antiandrogen, also called an androgen receptor inhibitor. It is used as part of hormone treatment for metastatic prostate cancer, normally together with an LHRH analog such as leuprolide or goserelin. By preventing male hormones called androgens from activating their receptors, bicalutamide reduces hormonal signals that can support prostate cancer growth. Ablu is an oral 50 mg tablet manufactured by Neon Laboratories Limited.
What it is used for
Bicalutamide 50 mg is indicated in combination with an LHRH analog for metastatic carcinoma of the prostate. It is not intended to replace the accompanying hormone-suppressing treatment. The 50 mg indication should not be confused with other bicalutamide strengths or treatment regimens, which may have different regulatory status and clinical uses.
How it works
Bicalutamide blocks androgen receptors, which are sites where hormones such as testosterone normally exert their effects. Prostate cancer cells can depend on androgen signaling for growth. Blocking these receptors reduces the ability of circulating androgens to stimulate the cancer cells. Bicalutamide is therefore used with treatment that lowers androgen production, such as an LHRH analog, to provide combined androgen blockade.
How it is taken
Bicalutamide 50 mg tablets are taken by mouth and may be taken with or without food. The prescribing information recommends taking the medicine at the same time each day, in the morning or evening, and starting it at the same time as the LHRH analog when used for its approved metastatic prostate cancer indication. If a dose is missed, take the next dose at the scheduled time; do not double the next dose. Follow the prescribed treatment plan and do not change or stop therapy without medical guidance.
Important warnings
Do not use bicalutamide if there is a known hypersensitivity to bicalutamide or its tablet ingredients. Serious liver injury, including hepatic failure and death, has been reported; liver function should be checked before treatment, regularly during the first months, and when symptoms suggest liver injury. Seek prompt medical assessment for jaundice, dark urine, persistent nausea, vomiting, abdominal pain, unusual tiredness, or loss of appetite. Bicalutamide can increase the anticoagulant effect of coumarin medicines such as warfarin, so PT/INR requires close monitoring. Use caution with CYP3A4 substrates because bicalutamide inhibits CYP3A4. Blood glucose monitoring may be appropriate when bicalutamide is combined with an LHRH agonist, particularly in people with diabetes. Photosensitivity, gynecomastia, breast pain, somnolence, and rare interstitial lung disease have also been reported.
Side effects and monitoring
Common effects reported with bicalutamide plus an LHRH analog include hot flashes, pain, weakness or asthenia, constipation, nausea, infection, swelling of the limbs, shortness of breath, diarrhea, blood in the urine, nighttime urination, and anemia. Other reported effects include dizziness, rash, breast enlargement or tenderness, raised liver enzymes, and changes in blood glucose. Serious or less common problems include severe liver injury, significant bleeding in people taking coumarin anticoagulants, hypersensitivity reactions, and interstitial lung disease. Seek medical attention for jaundice, unexplained bleeding or bruising, severe breathing difficulty, facial or throat swelling, or other severe reactions. Monitoring may include liver-function tests, PSA, PT/INR when coumarin anticoagulants are used, and blood glucose when clinically appropriate.
Pregnancy
Bicalutamide is not indicated for women and can cause fetal harm if exposure occurs during pregnancy. Male patients with female partners who can become pregnant should use effective contraception during treatment and for 130 days after the final dose.
Breastfeeding
Bicalutamide is not indicated for use in women. There are no human data on whether bicalutamide passes into breast milk or affects a breastfed infant or milk production; the medicine has been detected in animal milk.
Food and drink
Bicalutamide may be taken with or without food. Food does not have a clinically significant effect on its absorption.
Frequently asked questions
Is Ablu 50 mg the same medicine as abiraterone?
No. The verified active ingredient in Ablu 50 mg Tablet is bicalutamide 50 mg; abiraterone is a different prostate-cancer medicine.
Why is bicalutamide usually given with another hormone treatment?
Bicalutamide 50 mg is approved for metastatic prostate cancer in combination with an LHRH analog. The two medicines act at different points in androgen signaling: the LHRH treatment lowers androgen production while bicalutamide blocks androgen receptors.
Can I take bicalutamide with food?
Yes. Bicalutamide can be taken with or without food, and food does not meaningfully change its absorption.
What happens if I forget a bicalutamide dose?
Take the next dose at the normally scheduled time. Do not take the missed tablet or double the next dose.
Does bicalutamide commonly cause hot flashes or tiredness?
Yes. Hot flashes are among the most frequently reported effects when bicalutamide is used with an LHRH analog, and weakness or asthenia is also commonly reported.
Why are liver tests needed during treatment?
Bicalutamide can rarely cause serious liver injury. Liver-function testing helps detect changes early, and symptoms such as yellow skin or eyes, dark urine, persistent nausea, or marked fatigue should be reported promptly.
Can bicalutamide interact with warfarin?
Yes. Bicalutamide can increase the anticoagulant effect of coumarin medicines such as warfarin and has been associated with serious bleeding. PT/INR should be monitored closely when they are used together.
Can bicalutamide affect fertility?
It may. The prescribing information states that bicalutamide may impair male fertility and advises effective contraception for men with partners who can become pregnant during treatment and for 130 days after the final dose.
Sources
Medical information notice: This information does not replace advice from a qualified healthcare professional. Use prescription medicine only as directed by the prescriber and the approved product information.
| Packaging | Qty |
|---|---|
| Delivery Time | 6 To 15 days |
Related products
Hydrea 500 Mg (Hydroxyurea)
Imatib 100 Mg (Imatinib)
Mamofen 10 Mg (Tamoxifen Citrate)
Oxitan 100 Mg/25ml (Oxiplatin)
Oxitan 50 Mg/25ml (Oxiplatin)
Temoget 20 Mg (Temozolomide)
Votrient 400 Mg (Pazopanib)
Reviews
There are no reviews yet.